Genitourinary

Prostate

Castration-Resistant (CRPC)

Received at least 2 approved therapies for metastatic and/or castration resistant disease

PROS0110
Phase III
REGN4336 +/- Cemiplimab in Metastatic Castration Resistant Prostate Cancer
PI: Srinivas Sponsor: Regeneron Pharmaceuticals, Inc.

PROS0126
Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA & 67Cu-SAR-bisPSMA for ID & Treatment of Metastatic Castrate-Resistant Prostate Cancer
PI: Song Sponsor: Clarity Pharmaceuticals Ltd.

PROS0119
Phase I CO-94676 in Subjects With Metastatic Castration Resistant Prostate Cancer
PI: Srinivas Sponsor: Celgene Corporation

PROS0127
Phase I/IIa Theranostic Study of 64Cu-SAR-BBN & 67Cu-SAR-BBN for ID & Treatment of GRPR-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who are Ineligible for Therapy with 177Lu-PSMA-617
PI: Song Sponsor: Clarity Pharmaceuticals Ltd.

PSMA Negative

3rd Line Metastatic: Progressed on ADT and Secondary Hormonal Therapy as well as Taxane Unless Ineligible or Declined

Received at Least 1 Prior NHT Therapy for mCRPC

PROS0109
Pilot Study for Optimizing Mental Wellbeing & Heart Health for Black Patients w/ Prostate Cancer
PI: Fan Sponsor: Stanford University

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Trial Posting
Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu